[Syllabus]: Breast Cancer Staging and Treatment

Introduction

This course synthesizes a radiologist-focused overview of breast cancer staging and treatment, aligning imaging practices with clinical and pathologic decision-making. It emphasizes contemporary TNM staging, nodal anatomy and assessment, prognostic biomarkers and molecular subtypes, AJCC 8th edition prognostic staging, and the multidisciplinary management pathways (surgery, radiation, systemic therapy). Practical imaging pearls—how to measure tumor size, assess nodal disease, anticipate post-treatment changes, and recognize subtype-specific imaging patterns—are integrated to support accurate reporting and collaborative care.

Breast Cancer Staging Fundamentals (TNM Framework)

Staging remains anchored in the TNM system: Tumor (T, primary tumor size/extension), Nodes (N, regional nodal involvement), and Metastases (M, distant spread). Accurate staging begins with precise tumor measurement, appropriate nodal assessment (clinical, imaging, and pathology), and evaluation for metastatic disease. Staging guides prognosis and treatment selection.

Key Points

• Measure the greatest tumor dimension and round to the nearest millimeter; the largest focus determines T category in multifocal disease.
• Use the “m” suffix to denote multifocality (distinct from M for metastasis); apply the “y” prefix when staging after neoadjuvant therapy.
• Clinical nodal staging incorporates physical exam and imaging; pathologic staging follows excision.
• Distant metastasis is a binary clinical/imaging determination (M0 vs M1).
• Anatomic stage grouping is later refined by prognostic factors (grade, biomarkers).

Tumor (T) Classification Details

T category reflects size and local extension. Common categories: Tis (in situ), T1 (<2 cm), T2 (≥2 to <5 cm), T3 (≥5 cm), and T4 (extension beyond breast parenchyma). Distinguishing true skin involvement, chest wall invasion, and inflammatory patterns is critical.

Key Points

• Tis includes DCIS and Paget disease without invasive carcinoma.
• T1: <2 cm; T2: ≥2 to <5 cm; T3: ≥5 cm (use the single largest dimension).
• T4a: chest wall invasion beyond pectoralis; T4b: skin ulceration/satellite dermal foci/peau d’orange (not direct skin extension alone); T4c: both a and b; T4d: inflammatory breast cancer.
• Do not span normal tissue when measuring between separate foci; measure the dominant mass only.
• Bilateral primaries are staged independently; management is driven by the higher stage.

Regional Lymph Nodes: Anatomy and Staging

Regional nodal anatomy is organized by relation to pectoralis minor: Level I (lateral), Level II (beneath), Level III (medial). Clinical nodal category (N) is based on exam/imaging; pathologic nodal staging evaluates excised nodes and identifies micrometastases.

Key Points

• Levels: I (lateral to pectoralis minor), II (subpectoral), III (medial); axillary Levels I–II are the most accessible to ultrasound.
• Clinical categories: N0 (no regional nodes), N1 (mobile ipsilateral axillary I/II), N2a (fixed/ matted ipsilateral axillary I/II), N2b (internal mammary only), N3 (infraclavicular/IM+axillary/supraclavicular).
• Contralateral axillary nodes indicate distant metastasis; consider contralateral node biopsy when appropriate, after excluding a contralateral primary (MRI may help).
• FNA/core-confirmed nodal disease may be documented with an “F” suffix in clinical staging contexts.
• Prior axillary surgery may render nodes unassessable (Nx).

Distant Metastasis (M) Classification

Metastatic status is dichotomous by imaging/clinical assessment. Special subcategories identify isolated tumor cells in blood or marrow, which do not behave as overt metastases radiologically.

Key Points

• M0: no clinical/imaging evidence of distant metastasis.
• M0(i+): isolated tumor cells detected in blood/bone marrow (non-imaging descriptor).
• M1: distant metastasis present.
• Imaging selection should be tailored to clinical risk and stage.

Practical Anatomic Stage Grouping for Radiologists

While complete stage group tables are complex, radiologists can triage anatomically by size and nodal involvement, recognizing when advanced features (skin/chest wall involvement, supraclavicular nodes, distant disease) upstage patients.

Key Points

• Stage 0: in situ disease (DCIS).
• Stage I: T1 tumors with N0 or minimal nodal burden.
• Stage II: larger T or limited nodal disease; Stage III: extensive nodal involvement and/or T4 features.
• Stage IV: any T/N with M1.
• Use structured reporting to clearly convey T/N/M estimates and features that change stage (skin ulceration, chest wall invasion, supraclavicular nodes).

Histopathology and Tumor Grade

Histologic grade reflects deviation from normal breast epithelium, incorporating tubule formation, nuclear pleomorphism, and mitotic rate. Grade correlates with prognosis and helps define intrinsic subtype behavior.

Key Points

• Nottingham grading: sum of scores for tubules, nuclei, and mitoses (3–5 = grade 1; 6–7 = grade 2; 8–9 = grade 3).
• Higher grade correlates with worse prognosis and greater proliferative activity.
• Grade informs prognostic staging and systemic therapy choices.

Immunohistochemical Markers and Ancillary Studies

ER/PR and HER2 status, alongside proliferation indices, shape prognostic staging and targeted therapies. Pre-analytic variables (e.g., fixation) can impact assay accuracy.

Key Points

• ER/PR results are reported as percent positive cells; adequate formalin fixation (≥6 hours) is required for reliable staining.
• HER2 assessment typically begins with immunohistochemistry (IHC): high expression (3+) is positive; equivocal (2+) cases undergo further testing (e.g., FISH).
• Ki-67 reflects proliferation; >20% suggests high proliferative activity and may inform endocrine responsiveness.
• p63 highlights myoepithelial cells to distinguish DCIS from invasive carcinoma.
• E-cadherin helps differentiate ductal (retained) from lobular (lost) phenotype in difficult cases.

Molecular Subtypes and Imaging Correlates

Gene expression profiling defines luminal A/B, HER2-enriched, and basal-like (triple-negative) subtypes. These correlate with receptor status, grade, and characteristic imaging appearances that can cue radiologist suspicion.

Key Points

• Luminal A: ER/PR high, low Ki-67, low HER2; often grade 1; favorable prognosis; irregular hypoechoic masses on US; heterogeneous MRI enhancement; usually unifocal.
• Luminal B: ER/PR lower, Ki-67 high; HER2 variable; higher grade; similar imaging to luminal A; modest multifocality.
• HER2-enriched: ER/PR low, HER2 high; may show calcifications, echogenic halo on US, heterogeneous enhancement and washout kinetics on MRI.
• Basal/triple-negative: ER/PR/HER2 negative; high grade; often round/oval but non-circumscribed masses; hypoechoic to anechoic on US; rim enhancement and central necrosis on MRI—target viable peripheral tissue for biopsy.
• Recognize that round masses are not always benign; triple-negative cancers can mimic fibroadenomas by shape.

AJCC 8th Edition Prognostic Staging and Survival Implications

Prognostic staging integrates anatomic TNM with grade, ER/PR, HER2, and multigene assays. This individualizes stage assignment and better aligns with outcomes.

Key Points

• Approximately 40% of patients are reassigned when prognostic factors are included.
• ER-positive status confers superior survival across anatomic stages compared with ER-negative disease.
• Use validated tools/apps to assign prognostic stage; memorize high-yield patterns (e.g., small, ER+/HER2–, low-grade tumors often downstage).
• Radiology reports should provide precise anatomic detail to enable accurate integration with pathology/biomarkers.

Surgical Management Strategies

Surgical options include breast-conserving surgery (lumpectomy) and mastectomy. Selection depends on disease distribution, ability to achieve cosmesis, and eligibility for adjuvant radiation.

Key Points

• Breast-conserving therapy (lumpectomy + radiation) yields outcomes equivalent to mastectomy for stage I–II, unifocal tumors with clear margins.
• Consider mastectomy for multicentric tumors, poor anticipated cosmesis with lumpectomy, inability to receive RT (prior RT, scleroderma/lupus, pregnancy), inflammatory breast cancer, or patient preference.
• “Excisional biopsy” denotes removal of benign lesions; reserve “lumpectomy/partial mastectomy” for malignant disease.
• Upfront surgery versus neoadjuvant systemic therapy is individualized; radiology aids in mapping extent for surgical planning.

Mastectomy Types and Reconstruction (Imaging Implications)

Mastectomy variants and reconstruction techniques impact imaging appearances. Understanding flap anatomy prevents misinterpretation and guides appropriate modality selection.

Key Points

• Simple/subcutaneous mastectomy removes breast tissue (often nipple-sparing for prophylaxis or extensive DCIS); modified radical includes nipple and axillary dissection; radical mastectomy is now rare.
• Reconstruction options: tissue expanders/implants; myocutaneous flaps (TRAM, latissimus; pedicled or free).
• TRAM flap MRI delineates flap boundaries, pedicle, and denervated muscle; fat necrosis within flap is common and not breast tissue—localize suspected recurrent disease to residual native tissue.
• Mammography can be limited post-flap; MRI clarifies anatomy and suspicious findings.
• Achieving symmetry may require contralateral reduction/augmentation; flap options are typically single-use.

Breast-Conserving Therapy and When Not to Operate

Lumpectomy plus radiation reduces local recurrence and matches mastectomy survival in appropriate candidates. Surgery may be deferred or avoided in select scenarios.

Key Points

• Post-lumpectomy mammographic changes evolve: edema/skin thickening early; coarse calcifications at the bed (fat necrosis) can appear years later.
• Surgery is palliative in metastatic disease; frail/elderly patients may be managed systemically.
• Active surveillance for low-grade DCIS is under study; management is evolving.
• Persistent seromas can be prolonged after RT due to impaired lymphatic drainage.

Axillary Management: SLNB, ALND, and Z0011 Implications for Imaging

Axillary staging balances oncologic control with morbidity. Sentinel lymph node biopsy (SLNB) reduces lymphedema risk compared with axillary lymph node dissection (ALND); selective omission of completion ALND is evidence-based in limited nodal disease.

Key Points

• SLNB maps first-echelon drainage with blue dye and/or radiotracer; indicated in clinical stage I–II disease; accuracy reduced after prior surgery/RT.
• Negative SLNB predicts negative axilla in ~95% of cases; positive SLNB often represents the only involved node.
• ACOSOG Z0011: in clinically node-negative T1–T2 patients undergoing lumpectomy and whole-breast RT, with 1–2 positive sentinel nodes and no neoadjuvant therapy, completion ALND did not improve outcomes—ALND can be omitted.
• Radiology implications: Practices vary on routine axillary US/biopsy in the Z0011 era; align local imaging protocols with surgical team preferences.
• Lymphoscintigraphy may reveal non-axillary drainage (e.g., internal mammary); inform surgical planning.

Radiation Therapy: Indications, Techniques, and Imaging Sequelae

Adjuvant radiation lowers local recurrence after lumpectomy and is selectively used after mastectomy. Technique selection affects logistics, target coverage, and late effects.

Key Points

• Indications: after lumpectomy (standard); after mastectomy for positive margins, >4 positive nodes, large tumors, or extensive DCIS; include axilla if nodes are positive.
• Whole-breast external beam: typically daily fractions for ~6 weeks; hypofractionation delivers larger fractions over 1–3 weeks (not suitable when axillary coverage is needed).
• Partial-breast/conformal and intraoperative options exist; long-term equivalence data are still maturing.
• Expected imaging changes: skin thickening, trabecular edema, volume loss, fibrosis; recognize persistent seromas post-RT.
• Risks: lymphedema (with axillary fields), neuropathy, fractures, and a small long-latency risk of radiation-associated angiosarcoma; maintain vigilance for new palpable masses with negative mammography.

Brachytherapy (Partial Breast Irradiation)

Internal radiation can be delivered to the lumpectomy bed via interstitial seeds or balloon catheter systems to shorten treatment duration and localize dose.

Key Points

• Balloon catheter (e.g., MammoSite) placed intraoperatively or shortly after; seeds are temporarily loaded for 2–5 days in multiple sessions.
• CT planning confirms position and coverage.
• Early outcomes suggest equivalence to whole-breast RT in selected patients, but cosmesis may be inferior; long-term data continue to evolve.
• Use is selective and center-dependent.

Systemic Therapy: Chemotherapy Timing and Regimens

Cytotoxic chemotherapy is deployed adjuvantly to eradicate micrometastatic disease or neoadjuvantly to downstage tumors and assess in vivo sensitivity.

Key Points

• Common agents: anthracyclines (e.g., doxorubicin), taxanes (paclitaxel/docetaxel), cyclophosphamide, 5-FU, methotrexate, platinum compounds.
• Typical regimens include combinations such as AC→T; dose-dense schedules compress intervals.
• Adjuvant chemotherapy follows surgery; neoadjuvant therapy precedes surgery and enables breast conservation and response assessment.
• >50% tumor shrinkage on neoadjuvant therapy portends lower recurrence (approximately 5–10% in good responders).
• Best neoadjuvant responses occur in higher-grade, ER-negative, and HER2-positive tumors; triple-negative disease is often prioritized for early systemic therapy.

Integrating Imaging with Multidisciplinary Care

Radiologists influence staging, treatment selection, and surveillance through precise measurement, judicious biopsy targeting, and recognition of treatment-related changes.

Key Points

• Report the maximal tumor dimension and explicit T features (skin/chest wall involvement); avoid overestimation by excluding separate satellites and intervening normal tissue.
• Characterize axillary levels; when contralateral nodes are abnormal, targeted biopsy can establish M1—first exclude a contralateral primary (MRI as needed).
• For necrotic/rim-enhancing masses (often triple-negative), biopsy the viable peripheral rim to avoid nondiagnostic sampling.
• Understand reconstruction anatomy (e.g., TRAM flap boundaries) to localize suspected recurrence to residual native tissue.
• Communicate imaging-limiting factors post-RT and post-surgery; recommend modality adjustments (e.g., MRI) when mammography/US are insufficient.

Conclusion

Effective radiologic participation in breast cancer care requires mastery of TNM and prognostic staging, familiarity with biomarkers and molecular subtypes, and awareness of evolving surgical and radiation paradigms (e.g., SLNB, Z0011). Imaging must be precise in size and extent assessment, thoughtful in nodal evaluation, and nuanced in interpreting post-treatment changes and reconstruction anatomy. Close alignment with surgical and oncology teams ensures that imaging answers the clinical questions that drive individualized, evidence-based treatment.